Analysts expect Bio-Rad Laboratories, Inc. to report revenue of 627.89 M for Q3 26, against a range of 595.63 M to 660.14 M. The most recent reported quarter, Q2 26, came in at 651.00 M, a 0.4% beat against the 648.33 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 649.73 M | 667.50 M | 585.40 M | 651.60 M | 653.00 M | 693.20 M | 592.10 M | 651.00 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 634.26 M | 683.42 M | 583.73 M | 625.33 M | 717.77 M | 788.76 M | 661.80 M | 674.34 M | 660.14 M | 699.64 M | 691.63 M | 735.98 M | 747.51 M | 729.71 M | 649.39 M | 727.38 M | ||||||||||
| Low Estimate | 572.43 M | 602.74 M | 512.44 M | 576.66 M | 656.04 M | 669.07 M | 578.13 M | 622.33 M | 595.63 M | 619.65 M | 568.22 M | 681.73 M | 647.96 M | 657.91 M | 558.60 M | 605.53 M | ||||||||||
| Consensus Estimate | 603.34 M | 643.08 M | 548.09 M | 600.99 M | 686.91 M | 728.91 M | 619.97 M | 648.33 M | 627.89 M | 659.65 M | 629.93 M | 708.86 M | 697.74 M | 693.81 M | 603.99 M | 666.46 M |
Analysts expect Bio-Rad Laboratories, Inc. to report earnings per share of 2.36 for Q3 26, against a range of 2.13 to 2.59. The most recent reported quarter, Q2 26, came in at 2.62, a 43.2% beat against the 1.83 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.01 | 2.90 | 2.54 | 2.61 | 2.26 | 2.51 | 1.89 | 2.62 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 1.20 | 3.08 | 1.85 | 1.78 | 1.96 | 2.92 | 2.13 | 2.00 | 2.59 | 3.23 | 2.99 | 2.76 | 2.61 | 3.16 | 3.81 | 3.21 | ||||||||||
| Low Estimate | 1.02 | 2.80 | 1.61 | 1.60 | 1.68 | 2.74 | 1.97 | 1.66 | 2.13 | 2.97 | 2.73 | 2.52 | 2.39 | 2.66 | 3.21 | 2.99 | ||||||||||
| Consensus Estimate | 1.11 | 2.94 | 1.73 | 1.69 | 1.82 | 2.83 | 2.05 | 1.83 | 2.36 | 3.10 | 2.86 | 2.64 | 2.50 | 2.91 | 3.51 | 3.10 |
Pull Wall Street consensus for Bio-Rad Laboratories, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=BIO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "BIO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=BIO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();